EVALUATION OF HEPATIC AND RENAL FUNCTION ALTERATIONS ALONGSIDE HEMATOLOGICAL INDICES IN SYSTEMIC LUPUS ERYTHEMATOSUS

Saif Hussain; Khwam R. Hussein; Wissam R. Nayef

doi:10.61796/ijmi.v3i4.622

Authors

Saif A. Hussain
[email protected]
Department of Medical Laboratory Techniques, Basrah Health and Medical Technical College, Southern Technical University, Iraq
Khwam R. Hussein Al-Nasiriyah Technical Institute, Southern Technical University, Iraq https://orcid.org/0000-0003-4178-7922
Wissam R. Nayef Al-Nasiriyah Technical Institute, Southern Technical University, Iraq

Vol. 3 No. 4 (2026): International Journal Multidisciplinary (IJMI)

Articles

September 21, 2026

Downloads

VIEW ARTICLE

Abstract
How to Cite
Metrics
References
License

Objective: Systemic lupus erythematosus (SLE) is a common chronic autoimmune disease that can affect multiple organ systems plus autoantibody production and chronic inflammation. This study objective is to monitor changes in hepatic and renal function tests, hematologic alterations, and serum levels of autoimmune and inflammatory markers among Iraqi SLE patients. Method: A case-control study performed from November 2025 to April 2026 at Al-Karama Hospital and Al-Zahraa Hospital, Wasit Governorate, Iraq. Ninety subjects were included, 45 patients with SLE and 45 age- and sex-matched apparently healthy controls. Hematological parameters (WBC, Hb, PLT) were evaluated as well hepatic markers (ALT, AST), renal markers (blood urea, serum creatinine), autoimmune markers (ANA, anti-dsDNA) and inflammatory markers (CRP, ESR). All statistical analyses were conducted using IBM SPSS version 26. Results: Patients with SLE had significantly lower median hemoglobin (10.25 vs. 13.00 g/dL, P < 0.001) and platelet counts (240.00 vs. 288.00 × 10⁹/L, P = 0.001) than controls, while WBC counts showed no significant difference (P = 0.119). ALT, AST, blood urea, and serum creatinine levels were significantly higher in SLE patients compared with controls (P < 0.001 for all). Autoimmune (ANA, anti-dsDNA) and inflammatory markers (CRP, ESR) were also significantly elevated in patients (P < 0.001). No statistically significant differences were observed across age subgroups within the patient group. Novelty: SLE is associated with significant hematological alterations (anemia and reduced platelets), as well as marked hepatic and renal function impairments, alongside elevated autoimmune and inflammatory activity. Simultaneous monitoring of these markers provides essential clinical information for evaluating organ involvement and disease progression.

Hussain, S., Hussein, K. R., & Nayef, W. R. (2026). EVALUATION OF HEPATIC AND RENAL FUNCTION ALTERATIONS ALONGSIDE HEMATOLOGICAL INDICES IN SYSTEMIC LUPUS ERYTHEMATOSUS. International Journal Multidisciplinary (IJMI), 3(4), 33–46. https://doi.org/10.61796/ijmi.v3i4.622

Download Citation

C. H. Siegel and L. R. Sammaritano, “Systemic lupus erythematosus: a review,” Jama, vol. 331, no. 17, pp. 1480–1491, 2024.

A. Fanouriakis, N. Tziolos, G. Bertsias, and D. T. Boumpas, “Update οn the diagnosis and management of systemic lupus erythematosus,” Ann. Rheum. Dis., vol. 80, no. 1, pp. 14–25, 2021, doi: https://doi.org/10.1136/annrheumdis-2020-218272.

A. Al-Sheef et al., “Hematologic Manifestations in Systemic Lupus Erythematosus: A Systematic Review of Clinical Patterns, Prognostic Implications, and Epidemiology,” Pharm. Pract. (Granada)., vol. 23, no. 4, pp. 1–10, 2025.

Z. Yang, Y. Wu, S. Huang, J. Bao, L. Xu, and Y. Fan, “Risk factors associated with thrombocytopenia in systemic lupus erythematosus: a systematic review and meta-analysis,” Autoimmun. Rev., vol. 24, no. 2, p. 103721, 2025.

H.-J. Anders, R. Saxena, M. Zhao, I. Parodis, J. E. Salmon, and C. Mohan, “Lupus nephritis,” Nat. Rev. Dis. Prim., vol. 6, no. 1, p. 7, 2020, doi: 10.1038/s41572-019-0141-9.

F. K. Alduraibi and G. C. Tsokos, “Lupus nephritis biomarkers: a critical review,” Int. J. Mol. Sci., vol. 25, no. 2, p. 805, 2024.

E. Xagas, K. Drouzas, G. Liapis, and S. Lionaki, “Evidence based treatment for lupus nephritis: present perspectives and challenges,” Front. Nephrol., vol. 4, p. 1417026, 2024.

L. Zhou, S. Z. Cai, and L. L. Dong, “Recent advances in pathogenesis, diagnosis, and therapeutic approaches for digestive system involvement in systemic lupus erythematosus,” J. Dig. Dis., vol. 25, no. 7, pp. 410–423, 2024.

A. S. N. Al-Aboudi, J. T. Ahmed, and W. A.-A. Ali Farid, “Factors Influencing on the Consumption of SugarSweetened Beverages among Adults in Thi-Qar Hospitals, Iraq,” Int. J. Nutr. Sci., vol. 11, no. 2, pp. 312–320, 2026.

J. S. Nusbaum et al., “Sex differences in systemic lupus erythematosus: epidemiology, clinical considerations, and disease pathogenesis,” in Mayo Clinic Proceedings, Elsevier, 2020, pp. 384–394.

M. R. W. Barber et al., “Global epidemiology of systemic lupus erythematosus,” Nat. Rev. Rheumatol., vol. 17, no. 9, pp. 515–532, 2021, doi: 10.1038/s41584-021-00668-1.

A. A. Vieira, I. Almada-Correia, J. Inácio, P. Costa-Reis, and S. T. Da Rocha, “Female-bias in systemic lupus erythematosus: How much is the X chromosome to blame?,” Biol. Sex Differ., vol. 15, no. 1, p. 76, 2024.

A. M. Bertoli et al., “Systemic lupus erythematosus in a multiethnic US cohort LUMINA LI: Anaemia as a predictor of disease activity and damage accrual,” Rheumatology, vol. 46, no. 9, pp. 1471–1476, Sep. 2007, doi: 10.1093/rheumatology/kem153.

J. L. Chen et al., “Hematological abnormalities in systemic lupus erythematosus and clinical significance thereof: comparative analysis of 236 cases,” Zhonghua Yi Xue Za Zhi, vol. 87, no. 19, pp. 1330–1333, 2007.

A. Mititelu, M.-C. Onisâi, A. Roșca, and A. M. Vlădăreanu, “Current understanding of immune thrombocytopenia: a review of pathogenesis and treatment options,” Int. J. Mol. Sci., vol. 25, no. 4, p. 2163, 2024.

H. Zhao, S. Li, and R. Yang, “Thrombocytopenia in patients with systemic lupus erythematosus: significant in the clinical implication and prognosis,” Platelets, vol. 21, no. 5, pp. 380–385, 2010.

S. M. Abdel Galil, A. M. Edrees, A. K. Ajeeb, G. S. Aldoobi, M. El-Boshy, and W. Hussain, “Prognostic significance of platelet count in SLE patients,” Platelets, vol. 28, no. 2, pp. 203–207, 2017.

N. Hanata et al., “Immature platelet levels correlate with disease activity and predict treatment response of thrombocytopenia in lupus patients,” Lupus, vol. 30, no. 11, pp. 1764–1772, 2021.

M. Piga, A. Vacca, G. Porru, A. Cauli, and A. Mathieu, “Liver involvement in systemic lupus erythematosus: incidence, clinical course and outcome of lupus hepatitis,” Clin. Exp. Rheumatol., vol. 28, no. 4, p. 504, 2010.

M. Her, Y. Lee, E. Jung, T. Kim, and D. Kim, “Liver enzyme abnormalities in systemic lupus erythematosus: a focus on toxic hepatitis,” Rheumatol. Int., vol. 31, no. 1, pp. 79–84, 2011.

Z. Yang, Y. Liang, C. Li, W. Xi, and R. Zhong, “Associations of serum urea, creatinine and uric acid with clinical and laboratory features in patients with systemic lupus erythematosus,” Rheumatol. Int., vol. 32, no. 9, pp. 2715–2723, 2012.

H. Julkunen, S. Ekblom-Kullberg, and A. Miettinen, “Nonrenal and renal activity of systemic lupus erythematosus: a comparison of two anti-C1q and five anti-dsDNA assays and complement C3 and C4,” Rheumatol. Int., vol. 32, no. 8, pp. 2445–2451, 2012.

N. Leuchten et al., “Performance of Antinuclear Antibodies for Classifying Systemic Lupus Erythematosus: A Systematic Literature Review and Meta-Regression of Diagnostic Data,” Arthritis Care & Res., vol. 70, no. 3, pp. 428–438, 2018, doi: https://doi.org/10.1002/acr.23292.

J. Sota et al., “Anakinra drug retention rate and predictive factors of long-term response in systemic juvenile idiopathic arthritis and adult onset still disease,” Front. Pharmacol., vol. 10, p. 918, 2019.

H. Li, Y. Zheng, L. Chen, and S. Lin, “High titers of antinuclear antibody and the presence of multiple autoantibodies are highly suggestive of systemic lupus erythematosus.,” Sci. Rep., vol. 12, no. 1, p. 1687, Feb. 2022, doi: 10.1038/s41598-022-05807-6.

L. M. Vilá et al., “Systemic lupus erythematosus in a multiethnic cohort (LUMINA): XXIX. Elevation of erythrocyte sedimentation rate is associated with disease activity and damage accrual.,” J. Rheumatol., vol. 32, no. 11, pp. 2150 LP – 2155, Nov. 2005, [Online]. Available: http://www.jrheum.org/content/32/11/2150.abstract

V. Alende-Castro et al., “Factors influencing erythrocyte sedimentation rate in adults: new evidence for an old test,” Medicine (Baltimore)., vol. 98, no. 34, p. e16816, 2019.

E. V Barnes et al., “High sensitivity C-reactive protein in systemic lupus erythematosus: relation to disease activity, clinical presentation and implications for cardiovascular risk,” Lupus, vol. 14, no. 8, pp. 576–582, 2005.

Z. Rezaieyazdi et al., “Is there any correlation between high sensitive CRP and disease activity in systemic lupus erythematosus?,” Lupus, vol. 20, no. 14, pp. 1494–1500, 2011.

C. C. Mok, D. J. Birmingham, L. Y. Ho, L. A. Hebert, and B. H. Rovin, “High‐sensitivity C‐reactive protein, disease activity, and cardiovascular risk factors in systemic lupus erythematosus,” Arthritis Care Res. (Hoboken)., vol. 65, no. 3, pp. 441–447, 2013.

V. S. Schäfer, K. Weiß, A. Krause, and W. A. Schmidt, “Does erythrocyte sedimentation rate reflect and discriminate flare from infection in systemic lupus erythematosus? Correlation with clinical and laboratory parameters of disease activity.,” Clin. Rheumatol., vol. 37, no. 7, pp. 1835–1844, Jul. 2018, doi: 10.1007/s10067-018-4093-3.